Biotech Growth Opportunities

If you're a biotech job seeker waiting for the market to "get back to normal," stop waiting. This is the new normal. The S&P Biotech ETF is up 43% in 6 months. M&A is back. Companies are raising megarounds. But if you don't have clinical-stage experience and hard data on your CV, you're not in the conversation. The reality: companies that survived the 2022-2024 downturn don't hire like they used to. From 2020-2022, you could land a biotech role on potential. MBA with consulting experience? Welcome aboard. PhD with no industry experience? Here's a senior scientist role. Career switcher from tech? Let's build you a path. Those doors are closed. Today's HM need professionals who can execute immediately. They need people who've taken drugs through clinical trials, reg experts who've filed successful NDAs, and commercial leaders who've launched products. Why? Because funded companies can't afford to train anymore. Enveda raised $150M in a series D they weren't seeking. They have a dozen assets in pipeline with multiple clinical catalysts. Companies like Enveda are hiring. But they're hiring people who can accelerate clinical programs, not people who need 18 months to ramp up. Compare that to early-stage companies. Seed and series A volumes hit multi-quarter lows in Q2. These companies need to achieve broader milestones before they can raise again. They're running lean. They're not hiring. If you're job searching right now, here's what you need to understand: Target funded companies with data. If a biotech raised $100M+ in the last 6 months, they're hiring. If they haven't announced funding recently, they're probably not. Focus on hot areas. Obesity, AI drug discovery, and ADCs are pulling disproportionate capital. That's where the jobs are. Show results, not responsibilities. CVs need hard outcomes. "Led IND submission that resulted in FDA clearance in 8 months" beats "Responsible for IND preparation and submission." Hiring managers need proof you can deliver. Network with funded companies early. Connect with companies before they post roles. Build relationships before they start hiring. Accept that early-stage is risky right now. If you're considering an offer from a pre-Series A company, understand the risk. They might not raise their next round or might do a brutal down round that wipes out equity. Get more cash comp upfront. The market is functioning selectively. Companies with data are hiring professionals with experience. If that's not you yet, build that experience at your current company or target the few companies still willing to develop talent. Biotech jobs exist for people who can prove they deserve them.

I’ve been thinking a lot about the "leapfrog" effect we saw with Chinese automotive companies, and I'm now seeing a similar pattern emerge in another critical sector: biotechnology 🧬. It's a powerful shift away from traditional manufacturing into deep R&D, and it's happening faster than many realize. A recent Bloomberg article with data insights from Norstella put some hard numbers to this trend, which I found really insightful. Here are a few takeaways that stood out to me: 📈 Significant Pipeline Growth: The number of novel drugs entering development in China has grown remarkably, reaching over 1,250 last year. This puts it well ahead of the EU and brings it much closer to the US pipeline (~1,440). For context, that number was only 160 back in 2015. 🚀 Efficiency in Research: One of the key drivers is the speed of clinical trials. The data shows Chinese researchers can complete patient enrollment for certain trials in about half the time it takes in the US. This efficiency is a major accelerator for development. 🏆 A Shift in Perception: The old "copycat" label no longer fits the facts. We're seeing more Chinese-originated drugs earning expedited reviews from regulators like the FDA and EMA. Global players are also investing heavily, with deals like Pfizer's $1.2 billion upfront payment for a Chinese cancer drug signaling a new level of confidence. For me, the takeaway isn't just about one industry. It’s about a broader trend of high-level innovation becoming more globally distributed. The rise of China's biotech ecosystem is a dynamic I'm following closely, as it will surely reshape collaboration, competition, and investment in the life sciences for years to come. It’s definitely a space to watch. #China #Biotech #Innovation #Pharma #LifeSciences #DrugDiscovery #Technology #FutureofHealth #GlobalBusiness https://lnkd.in/gtvfCjyk

BREAKING: 💥 $3.5 BILLION investment and 850+ jobs 💪 coming from Eli Lilly and Company in a new #LehighValley 🏭 Advanced pharmaceutical manufacturing facility Today, Eli Lilly announced the largest life sciences investment in Pennsylvania history — a new, state-of-the-art pharmaceutical manufacturing facility in the Lehigh Valley. That headline alone is massive. But the bigger story is what this completes. Just months ago, Lilly launched Gateway Labs at Breakthrough Properties in Philadelphia, investing in early-stage science, founders, and translational innovation. Now, with this Fogelsville announcement, Lilly is anchoring the other end of the value chain — scaled, domestic biomanufacturing. Taken together, this isn’t coincidence. It’s stacking. Lilly is building vertically across Eastern Pennsylvania: • Discovery + startup enablement in Philadelphia • Talent, research, and clinical proximity across Greater Philly • Scaled, domestic biomanufacturing in the Lehigh Valley • Adjacency to established pharma operations like Sanofi This is how global pharma derisks the future: ➡️ Innovation close to academia and founders ➡️ Manufacturing close to infrastructure and workforce ➡️ Everything within a single, connected regional corridor For Pennsylvania, this marks a shift from winning projects to winning strategies. From Breakthrough Labs to billion-dollar production capacity, the state is now part of Lilly’s end-to-end operating footprint — not a one-off site. For founders, operators, workforce leaders, and investors, the message is clear: Eastern PA is no longer a “nice to have” on the life sciences map — it’s becoming a platform that ties in directly to New Jersey and Delaware to form an powerful megacluster of biopharmaceutical talent, infrastructure and innovation. Watch how this corridor evolves. Watch what gets built next. This is how ecosystems compound. More analysis coming on BioBuzz. #LifeSciences #Biomanufacturing #Biotech #Pharma #EcosystemBuilding #Pennsylvania #LehighValley #Philadelphia Read full story 👉 https://lnkd.in/eZP9nxER

Everyone keeps asking if biotech is back. It is. Just not in the way people think. At the start of this year, a handful of companies raised over a billion dollars in a matter of weeks. Aktis. Eikon. Generate. There was no celebration, no signal that the IPO window had swung open again. The money just…showed up. But only for a certain kind of company. That’s the part people are missing. For the better part of a decade, biotech was funded on possibility. If the science was interesting enough, the rest could be figured out later. Manufacturing, reimbursement, regulatory strategy those were downstream problems. Now they’re the only problems that matter. The question has quietly changed from “does this work?” to “can you actually build a company around it before you run out of money?” Most can’t. And the market has started to reflect that in ways that don’t look like a comeback at all. IPOs are happening, but only for companies that already look inevitable. M&A is doing the heavy lifting. Partnerships have stopped being strategic and started being structural. Even AI, which for a while could carry a story on its own, is being judged the same way everything else is. Not on what it promises, but on whether it shortens timelines, improves trials, or makes something cheaper. What looked like a downturn over the last two years was really something else entirely. A filtering process. About forty thousand people lost their jobs, capital pulled back, and a lot of companies quietly disappeared. That wasn’t contraction. It was selection. The tourists left. The operators stayed. Biotech didn’t lose its ambition. It just lost its tolerance for things that don’t translate into real patient impact. That’s a very different industry than the one we were all operating in a few years ago. I wrote about this shift and where it goes next in my latest piece for The Medicine Maker: https://lnkd.in/gRKjYCZ3 #biotech #lifesciences #venturecapital #healthcare #drugdevelopment #ai

Heidelberg’s biotech scene is going through growing pains. Several long-standing players, including Apogenix, Affimed (relocated to Mannheim), and Heidelberg Pharma, have recently faced painful setbacks. For those of us who’ve built companies here, these stories hit close to home. But I don’t see this as the end of Heidelberg’s biotech era. I see it as part of its evolution. Every innovation ecosystem goes through cycles of excitement, correction, and renewal. After a decade of growth driven by ambitious science and steady investments from a few key backers, our region is entering a new phase, one that asks tougher questions about business models, sustainability, and resilience. Biotech is, by nature, capital-intensive. Developing new drugs requires deep pockets and investors willing to stay patient through long timelines and high risks. Venture capital has been essential in turning groundbreaking science into clinical reality, and many investors show remarkable patience and belief in innovation. Yet, the challenge lies in the fit between the venture model and the realities of biotech innovation. VC funds often operate on cycles measured in years, while drug discovery and clinical validation unfold over decades. This mismatch can create pressure to move fast, sometimes faster than what a sound, sustainable business model allows. And it ties up resources that are needed elsewhere. That doesn’t make the venture approach wrong. It just means our ecosystem benefits from a broader mix of funding and business models, from partnerships and public grants to independent, organically growing companies. At PEPperPRINT GmbH, we’ve followed one of those alternative paths. We’re not developing drugs (at least not yet; our business model is different), but our experience shows that long-term, organic growth is a viable way to build a sustainable biotech business. The recent events surrounding Apogenix, Affimed, and Heidelberg Pharma (Heidelberg Pharma’s drug candidate HDP-101 is still promising) are not the end of the story. Heidelberg’s biotech scene is finding its footing, becoming wiser, more grounded, and more resilient. And that maturity will be the foundation for the next generation of scientific breakthroughs built here.

In August, biotech and pharma companies laid off 19,000 people, a 142% increase vs. August 2024 and the highest of any sector. Biotech just had one of its most damaging months in years. This excellent article by Boston Globe Media's Kara Miller illustrates the human and strategic cost. Take NextRNA: A Boston startup advancing non-coding RNA, backed by Bayer: When financing tightened and a July data package slipped, all 27 employees, including the founder-CEO, were let go. They are not alone. Kojin Therapeutics, Abata Therapeutics, iTeos, and others have shut down or cut deeply. Entire pipelines in oncology, neuro, immunology, and rare disease may never reach patients, not because the science failed, but because the environment did. Industry leaders quoted in the article highlight what’s at stake: • Founders who spent 5–7 years advancing programs can no longer finish the R&D cycle. • Thousands of experienced scientists are now navigating one of the toughest job markets in biotech’s history. • The knowledge embedded inside early teams, the hardest thing to rebuild disappears instantly. • Universities face financial strain and tighter immigration pathways, limiting the next generation of scientific talent. • The US downturn coincides with a rapidly strengthening biotech ecosystem in China, shifting where discovery and development are happening. For hubs like Boston, this is not abstract. Biotech is a major economic engine. Persistent shutdowns mean fewer high-paying jobs, less lab demand, and a potential outflow of talent. The long-term implication is clear: If early-stage biotech weakens, the entire innovation pipeline weakens. Large pharma depends on these companies to refill portfolios, especially heading into the 2028–2030 patent cliff. Signals for leadership teams: 1. Protect the core program: Prioritize assets with the strongest regulatory logic and payer rationale. 2. Build optionality early: Regional licensing, structured partnerships, and royalty-based capital extend runway without relying solely on equity markets. 3. Treat knowledge as a strategic asset: Codify scientific decisions, CMC logic, & development frameworks so progress is not lost during downturns. 4. Stay BD-ready: Clean IP, validated CMC, & a coherent value story shorten diligence and materially improve deal outcomes. 5. Track geopolitical shifts: If early US innovation contracts while China accelerates, the center of gravity for drug discovery may shift faster than expected. There are signs that the "biotech winter" is ending. That is good news. However, the US biotech sector needs to quickly become more efficient if it is to compete globally. Time to market remains long, costs high, and risks high. Driving efficiency in the system is essential to its survival in the long term. Unless companies protect their scientific core and stay transaction-ready, this cycle could define the next decade of medicines.

🧬 Boston’s biotech advantage may not primarily be science, talent, or venture capital. It may be the ability to create trusted, high-density learning systems. The recent Handelsblatt deep dive on Kendall Square highlights something often overlooked: Cambridge’s biotech rise was built not against regulation and public scrutiny — but alongside it. In the 1970s, recombinant DNA research triggered societal concerns. Cambridge responded with transparent governance, citizen involvement, and clear biosafety frameworks. Strict rules. Open dialogue. Scientific ambition. That combination created long-term trust — and with it, investment confidence, talent density, and translational velocity. Over time, an ecosystem emerged where universities, startups, pharma, investors, and clinicians continuously interact, reorganize, and learn around emerging science. Perhaps this is Boston’s real advantage: Not simply faster innovation — but faster collective learning. As biotech becomes increasingly integrated across science, clinical development, data, and capital, ecosystems that shorten learning cycles may ultimately define the next era of innovation. 📍Cambridge / Kendall Square 🔗 Inspired by a thoughtful recent Handelsblatt deep dive on Kendall Square. #Biotech #Innovation #Boston #KendallSquare #LifeSciences #Biotechnology #HealthcareInnovation #Ecosystems

VCs want Phase I data before they write cheques. But companies often need funding to get to Phase I. It's a Catch-22 that's killing brilliant science. I’ve been doing a lot of Executive Searches lately, and I’m seeing this everywhere… Companies with compelling preclinical data often struggle to raise Series A. VCs are demanding de-risked investments. Big pharma has become more selective. And breakthrough therapies are dying in the lab. The irony is that this "cautious" approach is creating MORE risk, not less. When you starve early-stage innovation, you get less diversification and fewer breakthrough therapies in the pipeline. (The VCs sitting on capital today will have fewer quality opportunities tomorrow.) So here’s what I’m telling the biotech leaders I work with… Stop chasing the VCs who want certainty. Focus on finding the rare investors who recognise that breakthrough innovation requires taking on breakthrough risk. (They exist. They're just harder to find.) The companies that survive this funding winter won't just be the ones with the best science. They’ll be the ones who dared to keep building when everyone else was paralysed by fear. Innovation doesn't wait for perfect conditions. Neither should you.

Lithuania’s life sciences sector is growing ~25% a year, already contributes about 2.7% of GDP, and exports roughly 87% of its output — which means this is not just a local startup story. It’s already an export engine. I’ve been mapping the Lithuania life sciences ecosystem, and the real insight for me is this: Most people still think Lithuania’s edge is just good science + lower-cost talent. It’s not. The companies most likely to win are the ones that can move across the 4 layers that actually turn Lithuanian research into investable, scalable biotech businesses: 1. Research Institutes This is where scientific credibility starts. Groups like Vilnius University, Center for Innovative Medicine, and Lithuanian University of Health Sciences matter because strong science is still the foundation of fundable biotech. 2. Startup Accelerators This is where research starts becoming a company. Programs like Startup Wise Guys, Baltic Sandbox, Startup Lithuania, EIT Health, and Vilnius Tech Park matter because many spinouts do not fail on science — they fail on commercialization sequencing. 3. Funding Programs This is where survival turns into momentum. Platforms like Innovation Agency Lithuania, Horizon Europe, EIC, EIT Health, Research Council of Lithuania, and Baltic Innovation Fund matter because biotech does not scale on product quality alone — it scales on capital timing. 4. Growth Investors This is where the ecosystem either compounds or stalls. Funds like Practica Capital, Iron Wolf Capital, Open Circle Capital, Coinvest Capital, BaltCap, and Change Ventures matter because the gap between “great local innovation” and “cross-border biotech company” is usually investor readiness, not technical brilliance. That’s why I don’t see this as just a Lithuania biotech map. I see it as a research-to-investment stack: research → acceleration → funding → investor readiness → global scale And that’s also where the bottleneck is for founders. A lot of life sciences startups in Lithuania can show: - strong science - credible R&D - early grant traction - promising platform or diagnostic potential But far fewer can show what investors actually underwrite: - commercialization logic - milestone packaging - fundability beyond grants - cross-border market readiness - a narrative that travels outside the Baltics That gap is where startups stay small. It’s also where the upside sits. For founders, getting this right means: faster fundraising, stronger investor confidence, less grant dependency, and better odds of scaling beyond research or contract work. That’s why I put together: - Life Sciences Research-to-Investment Map - blog post on how this ecosystem works - and a free Lithuania Life Sciences Research-to-Investment Diagnostic to help founders and investors see where a company is strong — and where it is likely to stall If you want the visual + blog + free tool, comment LITHUANIA and I’ll send it over.

Europe has an investment gap - and a very specific one at that: in biotechnology. This is despite the fact that Europe is a world leader when it comes to basic research and scientific excellence. Ground-breaking ideas are generated in universities and research institutes here, but only a fraction of them make their way into marketable products. The figures speak for themselves: in Germany, just 0.01% of GDP is invested in biotechnology. Europe averages 0.02 %. The USA? 0.05 %. This means that while billions are invested in biotech in the USA every year, start-ups and scale-ups in Europe are struggling to survive right from the start. ➡️ Why is this problematic? At a time when biotechnology is providing answers to global challenges (from mRNA vaccines and cancer therapies to sustainable food production), we cannot afford this investment gap. Europe has the talent. But it lacks the capital to turn it into products. And it is no coincidence that many technologies that are invented in Europe are made successful in the USA. Why? 3 reasons: 1/ Better funding opportunities. The USA has a deep capital market that is willing to take risks. In 2023 alone, over 14 billion US dollars flowed into biotech start-ups there - many times more than what is available in Europe. 2/ Greater risk appetite among investors. While European investors often focus on security, US investors consciously invest in high-risk/high-reward projects. 3/ Faster regulatory processes. Anyone who founds a biotech start-up in the USA not only has more capital at their disposal, but also gets through the approval process more quickly. So what needs to happen? ✅ Massively increase public funding programs for biotech projects ✅ Create tax incentives for investors who invest in venture capital ✅ Reduce bureaucracy to make investments less complicated A look at successful locations shows that it is not enough to have outstanding researchers. You also need a functioning innovation ecosystem - and that starts with the right political decisions. If Europe wants to survive in the global biotech competition, this investment gap must be closed.